These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 30323086

  • 1. First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition.
    Lin VTG, Nabell LM, Spencer SA, Carroll WR, Harada S, Yang ES.
    J Natl Compr Canc Netw; 2018 Oct; 16(10):1166-1170. PubMed ID: 30323086
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
    Gargano SM, Senarathne W, Feldman R, Florento E, Stafford P, Swensen J, Vranic S, Gatalica Z.
    Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
    [Abstract] [Full Text] [Related]

  • 5. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
    Geukes Foppen MH, Boogerd W, Blank CU, van Thienen JV, Haanen JB, Brandsma D.
    Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.
    Schmitt NC, Kang H, Sharma A.
    Oral Oncol; 2017 Nov; 74():40-48. PubMed ID: 29103750
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.
    Chapman PB, Solit DB, Rosen N.
    Cancer Cell; 2014 Nov 10; 26(5):603-4. PubMed ID: 25517746
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.
    Burkart J, Owen D, Shah MH, Abdel-Misih SRZ, Roychowdhury S, Wesolowski R, Haraldsdottir S, Reeser JW, Samorodnitsky E, Smith A, Konda B.
    J Natl Compr Canc Netw; 2018 Sep 10; 16(9):1035-1040. PubMed ID: 30181415
    [Abstract] [Full Text] [Related]

  • 17. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.
    Schreuer M, Jansen Y, Planken S, Chevolet I, Seremet T, Kruse V, Neyns B.
    Lancet Oncol; 2017 Apr 10; 18(4):464-472. PubMed ID: 28268064
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Solitary adrenal metastasis from salivary duct carcinoma of the parotid gland successfully treated by surgery: A case report.
    Amano Y, Tsuji K, Kihara A, Matsubara D, Fukushima N, Nishino H, Niki T.
    Medicine (Baltimore); 2021 Jan 15; 100(2):e24011. PubMed ID: 33466142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.